Literature DB >> 28280627

Minimally invasive Ivor-Lewis esophagectomy for esophageal cancer with right aortic arch.

Jeremy Linson1, Michael Latzko1, Bestoun Ahmed1, Ziad Awad1.   

Abstract

Right aortic arch (RAA) is a rare congenital vascular abnormality in which the aorta descends in the right thorax and encircles the esophagus. Historically, esophagectomy for patients for RAA is done through a left thoracotomy as exposure and mobilization of the esophagus is difficult through a right thoracotomy. A 73-year-old male was found to have an esophageal adenocarcinoma. Endoscopic ultrasound showed a T3N0 lesion in the lower third of the esophagus. PET CT demonstrated a circumferential lesion without evidence of distant disease or involved lymph nodes and a RAA which was not associated with congenital heart disease or symptoms. The patient received neo-adjuvant chemoradiation (50.4 Gy) with carboplatin and paclitaxel. Minimally invasive Ivor-Lewis esophagectomy (MIE) utilizing conventional right thoracoscopy was done. Esophageal mobilization, transection and mediastinal lymph node dissection was performed through anteriorly placed trocars, thereby avoiding the right side descending aorta that is lying anterior and to the right of the esophagus. In this video we demonstrate MIE utilizing right thoracoscopy. Total operative time was 250 minutes and the patient was discharged home on post-operative day 8. Final pathology showed complete pathological response, with 0/22 involved lymph nodes and uninvolved surgical margins. Minimally invasive esophagectomy has been reported to deliver superior outcomes to the open approach. MIE can be performed in selected patients with RAA, and herein we demonstrate a minimally invasive option for the treatment of distal esophageal cancer in patients with RAA. To our knowledge this is the 1st reported case in the English literature utilizing this approach in patient with RAA.

Entities:  

Keywords:  Esophageal cancer; esophageal surgery; laparoscopy

Year:  2017        PMID: 28280627      PMCID: PMC5334045          DOI: 10.21037/jgo.2016.12.01

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  5 in total

1.  Outcomes after minimally invasive esophagectomy: review of over 1000 patients.

Authors:  James D Luketich; Arjun Pennathur; Omar Awais; Ryan M Levy; Samuel Keeley; Manisha Shende; Neil A Christie; Benny Weksler; Rodney J Landreneau; Ghulam Abbas; Matthew J Schuchert; Katie S Nason
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

2.  Thoracoscopic esophagectomy in the prone position for esophageal cancer with right aortic arch: case report.

Authors:  Shingo Kanaji; Tetsu Nakamura; Yasunori Otowa; Masashi Yamamoto; Kimihiro Yamashita; Tatsuya Imanishi; Yasuo Sumi; Satoshi Suzuki; Kenichi Tanaka; Yoshihiro Kakeji
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

3.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

4.  Esophageal cancer associated with right aortic arch: a case study.

Authors:  Takeshi Shimakawa; Yoshihiko Naritaka; Yoshihisa Wagatuma; Souichi Konno; Takao Katsube; Kenji Ogawa
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

5.  Successful resection of esophageal cancer with right aortic arch by video-assisted thoracoscopic surgery: a case report.

Authors:  Naoshi Kubo; Masaichi Ohira; Tomohiro Lee; Katsunobu Sakurai; Takahiro Toyokawa; Hiroaki Tanaka; Kazuya Muguruma; Kenjiro Kimura; Hisashi Nagahara; Eiji Noda; Ryosuke Amano; Hiroshi Ohtani; Yoshito Yamashita; Masakazu Yashiro; Kiyoshi Maeda; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.